Aclaris Therapeutics (ACRS) Gross Margin (2017 - 2026)

Aclaris Therapeutics' Gross Margin history runs 10 years deep, the most recent figure standing at 80.21% for Q1 2026.

• On a quarterly basis, Gross Margin rose 1499.0% year-over-year to 80.21% in Q1 2026; TTM through Mar 2026 was 76.34%, a 966.0% decrease from a year earlier, with the FY2025 full-year figure at 73.28%, down 1180.0% from the prior year.
• Gross Margin climbed to 80.21% in Q1 2026 per ACRS's latest filing, from 58.92% in the prior quarter.
• Across five years, Gross Margin topped out at 95.87% in Q4 2023 and bottomed at 20.51% in Q1 2022.
• The 5-year median for Gross Margin is 77.44% (2024), against an average of 71.38%.
• Across the five-year window, Gross Margin surged 6524 bps in 2022 and sank 3343 bps in 2025, its largest moves.
• Year by year, Gross Margin stood at 88.69% in 2022, then increased by 8 bps to 95.87% in 2023, then declined by 4 bps to 92.35% in 2024, then sank by 36 bps to 58.92% in 2025, then surged by 36 bps to 80.21% in 2026.
• Per Business Quant, the three latest ACRS Gross Margin figures stand at 80.21% (Q1 2026), 58.92% (Q4 2025), and 83.69% (Q3 2025).